Latest Csl News

Page 4 of 6
CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.
Ada Torres
Ada Torres
11 Feb 2026
CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.
Ada Torres
Ada Torres
10 Feb 2026
Magnetite Mines broadens its strategic partnerships and progresses key approvals for the Razorback Iron Ore Project, while uncovering new rare earth mineralisation and expanding its green iron consortium.
Maxwell Dee
Maxwell Dee
30 Jan 2026
AMCIL Limited reported a 14.8% increase in half-year profit to $4.1 million, maintaining its interim dividend amid a portfolio return that lagged the ASX 200 benchmark.
Claire Turing
Claire Turing
22 Jan 2026
Australian Foundation Investment Company reports a 4.6% decline in half-year profit but sustains its interim dividend with a special payout, while portfolio returns lag the benchmark.
Victor Sage
Victor Sage
21 Jan 2026
Djerriwarrh Investments Limited reported a $20.7 million half-year profit with a steady fully franked dividend, despite portfolio returns lagging the ASX 200. The company signals a strategic pivot with quarterly dividends and selective portfolio adjustments.
Victor Sage
Victor Sage
19 Jan 2026
Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.
Ada Torres
Ada Torres
24 Nov 2025
FSI’s FY2025 portfolio posted a modest 5.0% return, trailing the ASX All Ordinaries Index, while maintaining dividend growth and planning a strategic move into pre-IPO investments.
Claire Turing
Claire Turing
6 Nov 2025
CSL Limited’s latest Capital Markets Day presentation highlights CSL Seqirus’s strategic positioning to capitalize on a recovering US influenza vaccine market and global growth opportunities.
Ada Torres
Ada Torres
5 Nov 2025
CSL Limited has revised its financial outlook for FY26, citing lower US influenza vaccination rates and government cost controls in China, while postponing the planned demerger of its Seqirus vaccine business and announcing a major cost-saving program.
Ada Torres
Ada Torres
28 Oct 2025
Whitefield Industrials reports a $10.5 million net profit for H1 2026, with a strong 17.1% annualised return over three years, maintaining its track record of benchmark outperformance and announcing a 10.5 cent fully franked dividend.
Claire Turing
Claire Turing
27 Oct 2025
CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.
Ada Torres
Ada Torres
16 Sept 2025

Browse the archive

Full archive